LUND, Sweden, Nov. 29, 2019 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced that
the company has appointed Dr Malin
Carlsson as Chief Operating Officer. She most recently comes
from a position as Vice President, Head of Translational Medicine
at Ferring Pharmaceuticals in Copenhagen.
In Alligator's management team, Malin
Carlsson will have overall responsibility for the company's
clinical projects, with emphasis on the development plans for the
candidate drugs mitazalimab (ADC-1013) and ATOR-1015, both of which
are planned to start phase II clinical studies in 2020.
"I am very pleased with the successful recruitment of
Malin Carlsson to Alligator. Her
international experience in leading clinical development and in
building development organizations will significantly strengthen
our clinical capacity. This is crucial in the phase we are in now,
with two products on the way to phase II and another product in
clinical phase I. We look forward to welcoming Malin to
Lund and to our management team,"
said Per Norlén, CEO of Alligator Bioscience.
Malin Carlsson is a medical
doctor with specialist qualifications and a PhD in clinical
immunology. She also has many years of industrial experience from
various senior roles in major international pharmaceutical
companies such as AstraZeneca, Nycomed, Takeda and Ferring.
Malin Carlsson will assume the role
of Chief Operating Officer (COO) at Alligator on January 1, 2020.
"To be able to contribute and develop the cancer treatment of
the future is an opportunity that is too good to turn down. With my
broad experience from clinical studies in immunology and of
strategic organizational development in the pharmaceutical
industry, I hope to add know-how that will make a difference. I
really look forward to becoming part of Alligator," said
Malin Carlsson.
The information was submitted for publication, through the
agency of the contact person set out above, at 08:30 a.m. CET on November
29, 2019.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes six lead clinical and
preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015,
ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics
Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai
Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
For further information:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-appoints-chief-operating-officer,c2975516
The following files are available for download:
https://mb.cision.com/Main/12681/2975516/1152224.pdf
|
Alligator Bioscience
AB appoints Chief Operating Officer
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-appoints-chief-operating-officer-300966747.html
SOURCE Alligator Bioscience